Insights

  • Home
  • Insights
  • Genentech to Defend 3 of 4 Herceptin® Patents Challenged by Hospira, PTAB Litigation Blog

Share

Genentech to Defend 3 of 4 Herceptin® Patents Challenged by Hospira, <i>PTAB Litigation Blog</i>

Genentech to Defend 3 of 4 Herceptin® Patents Challenged by Hospira, PTAB Litigation Blog

August 2017 Blog

Visit the Jones Day PTAB Litigation Blog.

At least 19 IPRs have been filed against seven of Genentech’s patents covering its blockbuster antibody drug Herceptin® (trastuzumab). On July 27, 2017, the PTAB instituted IPRs filed by Hospira, Inc. (a subsidiary of Pfizer) against three Herceptin® patents, and denied an IPR for a fourth Herceptin® patent.

The four challenged patents (U.S. Patent Nos. 6,627,196; 7,371,379; 7,846,441; and 7,892,549) belong to two different families, with one family covering the use of Herceptin® in combination therapies and the other covering dosing regimens for treating disorders characterized by overexpression of ErbB2.

Read the full article at ptablitigationblog.com.

You May Also Be Interested In

April 2024 White Paper

Fifteenth Anniversary Update: Annotated Local Patent Rules for the Northern District of Illinois

April 2024 Blog

Availability of Document on Government Website Insufficient for Institution, PTAB Litigation Blog

April 2024 Blog

Petition Denied for Lacking Section 112(f) Construction and Fintiv, PTAB Litigation Blog

April 2024 Blog

Director Review: PTAB Must Articulate Bases for Section 325(d) Denial, PTAB Litigation Blog

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.